Minimal Residual Disease and Hematologic Malignancies: Why, How, Who, and When?

ONLINECME



Date & Location
Wednesday, March 6, 2019, 12:00 AM - Friday, March 6, 2020, 12:00 PM

Course Overview

A 5000-word text-based, CME-certified activity that will provide learners with an overview of the latest information about MRD in ALL, MM, AML, and CLL. The goal of this activity is to assist front-line practitioners with integrating the most current clinical data and recommendations into everyday clinical practice.

Content last reviewed: March 6, 2019


Target Audience
Specialties - INTERNAL MEDICINE - Hematology, INTERNAL MEDICINE - Medical Oncology

Learning Objectives
  1. Demonstrate greater competence in using MRD analysis as an essential component of patient evaluation over course of therapy for ALL
  2. Demonstrate greater confidence in ability to use MRD status to evaluate response to therapy for patients with MM
  3. Demonstrate increased knowledge of emerging role of MRD analysis in management of patients with AML
  4. Demonstrate increased knowledge of potential role of MRD analysis in making therapeutic decisions for patients with CLL

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  

Designation of Credit


Credits
AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance / Participation (1.00 hours)